US EditionPublished • loading... • Updated
FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
Summary by Watauga Democrat
25 Articles
25 Articles
Newsbug.info+23 Reposted by 23 other sources
FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.
Coverage Details
Total News Sources25
Leaning Left3Leaning Right5Center5Last UpdatedBias Distribution39% Center, 38% Right
Bias Distribution
- 39% of the sources are Center, 38% of the sources lean Right
39% Center
L 23%
C 39%
R 38%
Factuality
To view factuality data please Upgrade to Premium
